1. Home
  2. RWT vs GYRE Comparison

RWT vs GYRE Comparison

Compare RWT & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Redwood Trust Inc.

RWT

Redwood Trust Inc.

HOLD

Current Price

$4.43

Market Cap

597.9M

Sector

Real Estate

ML Signal

HOLD

Logo Gyre Therapeutics Inc.

GYRE

Gyre Therapeutics Inc.

HOLD

Current Price

$6.40

Market Cap

606.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RWT
GYRE
Founded
1994
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
597.9M
606.4M
IPO Year
1996
2004

Fundamental Metrics

Financial Performance
Metric
RWT
GYRE
Price
$4.43
$6.40
Analyst Decision
Buy
Strong Buy
Analyst Count
7
2
Target Price
$6.82
$17.00
AVG Volume (30 Days)
1.4M
46.1K
Earning Date
04-29-2026
05-08-2026
Dividend Yield
12.83%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$275,000.00
Revenue This Year
$26.59
$19.88
Revenue Next Year
$22.21
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.19
$5.44
52 Week High
$6.97
$9.42

Technical Indicators

Market Signals
Indicator
RWT
GYRE
Relative Strength Index (RSI) 33.18 45.93
Support Level $4.19 $5.78
Resistance Level $4.93 $6.66
Average True Range (ATR) 0.10 0.27
MACD -0.02 -0.05
Stochastic Oscillator 0.00 8.76

Price Performance

Historical Comparison
RWT
GYRE

About RWT Redwood Trust Inc.

Redwood Trust Inc is a specialty finance company focused on several distinct areas of housing credit. The company delivers customized housing credit investments to a diverse mix of investors through securitization platforms, whole-loan distribution activities, and its publicly traded securities. The company has four reportable segments: Sequoia Mortgage Banking, CoreVest Mortgage Banking, Redwood Investments, and Legacy Investments. Maximum revenue is generated from the Sequoia Mortgage Banking segment, comprising a mortgage loan conduit that acquires residential consumer loans from third-party originators for subsequent sale to whole loan buyers, securitization through its SEMT private-label securitization program, or transfer into its Redwood Investments portfolio.

About GYRE Gyre Therapeutics Inc.

Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Share on Social Networks: